BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $15.20B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 3.55M
Average 2.49M
BBIO Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
BridgeBio Pharma, Inc.NASDAQ: BBIO
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses remains negative
Q2 FY2026 other income / expenses was -$48.81M, compared with -$47.38M a year earlier. Trailing-twelve-month other income / expenses was -$162.69M.
Context
- Other income / expenses amounted to 33.0% of revenue in FY2025, up 10.2 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$48.81M or moves back toward the trailing-twelve-month quarterly average of -$40.67M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (165.9M) USD
- Year-over-year change
- -426.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (165.9M) | -426.7% |
| FY2024 | 2024-12-31 | 50.78M | +210.7% |
| FY2023 | 2023-12-31 | (45.88M) | -266.5% |
| FY2022 | 2022-12-31 | 27.55M | +380.5% |
| FY2021 | 2021-12-31 | (9.82M) | — |
Other Income / Expenses vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -29.8% is the 5th highest of 11, against a peer median of -36.5%.
- Other income / expenses amounts to 22.8% of revenue for BBIO, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €48.89M EUR | +163.0% | — | 4.0% | |
| LTM Jun 2026 | $31.35M USD | -42.6% | +42.7% | 869.8% | |
| LTM Sep 2026 | $21.61M USD | +11.8% | -76.4% | 2.3% | |
| LTM Mar 2026 | $11.51M USD | +295.2% | — | 57.5% | |
| LTM Sep 2026 | -$4.74M USD | -154.6% | — | 830.9% | |
| LTM Sep 2026 | -$26.23M USD | -1115.7% | — | 4.0% | |
| LTM Mar 2026 | -$43.77M USD | -30.4% | — | 6.5% | |
| LTM Jun 2026 | -$162.69M USD | -29.8% | — | 22.8% | |
| LTM Jun 2026 | -$183.33M USD | -250.6% | — | 18.2% | |
| LTM Jun 2026 | -$200.21M USD | -0.4% | — | 4.2% | |
| LTM Sep 2026 | -$49.83B USD | -78235.6% | — | 4.9% | |
| Peer median (excluding BBIO) | — | -36.5% | -16.9% | 5.7% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 69.72M | 77.65M | 9.3M | 221.9M | 502.08M |
| Cost of Revenue | 3.11M | 3.43M | 2.45M | 3.88M | 28.27M |
| Gross Profit | 66.6M | 74.21M | 6.86M | 218.02M | 473.81M |
| Gross Margin | 95.5% | 95.6% | 73.7% | 98.3% | 94.4% |
| Research & Development | 451.02M | 399.46M | 455.71M | 506.46M | 477.54M |
| Selling, General & Admin | 192.21M | 143.19M | 150.59M | 288.93M | 555.14M |
| Operating Expenses | 643.23M | 586.42M | 614.23M | 811M | 1.04B |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| EBITDA | (533.83M) | (397.44M) | (565.47M) | (436.83M) | (676.45M) |
| EBITDA Margin | -765.7% | -511.9% | -6078.3% | -196.9% | -134.7% |
| Operating Income | (576.63M) | (512.2M) | (607.37M) | (592.97M) | (569.09M) |
| Operating Margin | -827.1% | -659.6% | -6528.8% | -267.2% | -113.3% |
| Interest Income | 1.13M | 7.54M | 18.04M | 17.25M | 19.85M |
| Interest Expense | 46.78M | 80.44M | 81.29M | 99.29M | 53.1M |
| Other Income / Expenses | (9.82M) | 27.55M | (45.88M) | 50.78M | (165.9M) |
| Income Before Tax | (586.45M) | (484.65M) | (653.25M) | (542.19M) | (734.99M) |
| Pre-Tax Margin | -841.2% | -624.2% | -7021.9% | -244.3% | -146.4% |
| Income Tax Expense | 0 | 0 | 0 | 1.15M | 555K |
| Net Income | (562.54M) | (481.18M) | (643.2M) | (535.76M) | (729.31M) |
| Net Margin | -806.9% | -619.7% | -6913.9% | -241.4% | -145.3% |
| EPS (Basic) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| EPS (Diluted) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| Weighted Avg Shares | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
| Weighted Avg Shares (Diluted) | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$78.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.